BRIEF-Immunomedics reports preclinical study presented at 2017 AACR annual meeting
April 04, 2017 at 08:31 AM EDT
* Immunomedics reports immu-132 delivers high levels of sn-38 that overcome chemoresistant tumors with moderate to strong trop-2 expression Source text for Eikon: Further company coverage:
